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Background: Osteoarthritis (OA) is a heterogeneous group of conditions with disturbed integrity of articular cartilage
and changes in the underlying bone. The pathogenesis of OA is multifactorial and not just a disease of older people.
Hydroxychloroquine (HCQ) is a disease-modifying anti-rheumatic drug (DMARD) typically used for the treatment of
various rheumatic and dermatologic diseases. Three studies of HCQ in OA, including one abstract and one letter, are
available and use a wide variety of outcome measures in small patient populations. Despite initial evidence for good
efficacy of HCQ, there has been no randomized, double-blind, and placebo-controlled trial in a larger patient group. In
the European League Against Rheumatism (EULAR), evidence-based recommendations for the management of hand
OA, HCQ was not included as a therapeutic option because of the current lack of randomized clinical trials.
Methods/Design: OA TREAT is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
A total of 510 subjects with inflammatory and erosive hand OA, according to the classification criteria of the American
College of Rheumatology (ACR), with recent X-ray will be recruited across outpatient sites, hospitals and universities in
Germany. Patients are randomized 1:1 to active treatment (HCQ 200 to 400 mg per day) or placebo for 52 weeks. Both
groups receive standard therapy (non-steroidal anti-inflammatory drugs [NSAID], coxibs) for OA treatment, taken
steadily two weeks before enrollment and continued further afterwards. If disease activity increases, the dose of NSAID/
coxibs can be increased according to the drug recommendation. The co-primary clinical endpoints are the changes in
Australian-Canadian OA Index (AUSCAN, German version) dimensions for pain and hand disability at week 52. The
co-primary radiographic endpoint is the radiographic progression from baseline to week 52. A multiple endpoint test
and analysis of covariance will be used to compare changes between groups. All analyses will be conducted on an
intention-to-treat basis.
Discussion: The OA TREAT trial will examine the clinical and radiological efficacy and safety of HCQ as a treatment
option for inflammatory and erosive OA over 12 months. OA TREAT focuses on erosive hand OA in contrast to other
current studies on symptomatic hand OA, for example, HERO [Trials 14:64, 2013].
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Osteoarthritis (OA) is a heterogeneous group of conditions
with defective integrity of articular cartilage and changes in
the underlying bone. The pathogenesis is multifactorial
and involves a complex interplay of genetic, metabolic,
biochemical, and biomechanical factors with variable com-
ponents of inflammation. Subsets of patients with OA de-
velop an inflammatory and erosive form of the disease. As
one of the most prevalent musculoskeletal diseases, the
condition leads to pain in and around the affected joints
and to swelling, stiffness, deformity, and gradual loss of
function [1,2]. This disease not only affects older people,
but also the younger working population. The pathologic
mechanisms and its triggers are still not known. Treatment
options are limited to symptomatic therapy and (rarely)
surgical intervention. Compared to the research results of
hip OA and knee OA, there are very few basic research ac-
tivities in the field of hand OA. However, over the past
15 years, there has been an increase in the number of clin-
ical trials in OA including hand OA. Nevertheless, effective
treatments for OA are limited, since many treatments have
only small symptom-relieving effects. There are few thera-
peutic studies in patients with hand OA investigating oral
non-steroidal anti-inflammatory drugs (NSAIDs), topical
NSAIDs, and other topical drugs. For the symptomatic
slow-acting drugs in OA (SYSADOA) and disease modify-
ing drugs in OA (DMOADS), very few studies can be iden-
tified, and unfortunately, many publications are available
only as abstracts. Most of these randomized controlled tri-
als (RCTs) used a broad range of outcome measures, some
of them poorly standardized. Differences in disease defin-
ition between studies make it hard to generalize the results
for clinical practice. Many studies were underpowered or
planned as pilot studies [3,4]. HCQ (originally an antimalar-
ial drug) is a disease modifying drug (DMARD) used for in-
flammatory erosive OA in clinical practice. HCQ has been
used since the 1950s for the treatment of various rheumatic
and dermatologic diseases. Current research has further en-
hanced our understanding of the pharmacologic mecha-
nisms of these drugs, involving inhibition of endosomal
toll-like receptor (TLR) signaling, which inhibits B cell and
dendritic cell activation [5]. With this understanding, the
use of these medications in rheumatology is broadening.
In OA and hand OA, symptomatic therapy with NSAIDs
or coxibs is the most frequently administered treatment.
Regarding tumor necrosis factor (TNF)-α-antagonists, one
pilot study with adalimumab (ADA) in patients with ero-
sive/inflammatory OA (EOA) of the hands demonstrated
that ADA was well tolerated; however, treatment with ADA
for three months did not significantly improve signs and
symptoms of EOA, and most patients did not achieve an
ACR20 [6]. Three studies of HCQ in EOA, including one
abstract and one letter, are available. HCQ at a dose of 200
to 400 mg daily was effective in seven patients withevidence of EOA on X-ray. This study was an open retro-
spective study [7]. The result of an open retrospective study
of eight patients with EOA of proximal interphalangeal
(PIP) and distal interphalangeal (DIP) joints and a dosage
of 400 mg daily demonstrated that in six patients an
improvement of synovitis, morning stiffness, and global
assessment was seen [8]. One prospective, randomized,
double-blind, and placebo-controlled trial in 15 patients
with EOA of PIP and DIP joints and radiological changes
consistent with OA showed that HCQ was more effective
than placebo on clinical (Ritchie-Index) and biological as-
sessments (ESR, IL_2receptor level) [9]. To summarize, the
review of published data on hand OA raises more questions
than it answers with regard to the evaluation of therapeutic
agents in hand OA. Moreover, the few RCTs that have been
performed were in small patient populations and lack stan-
dardized outcome assessments [4]. A task force of the
Osteoarthritis Research Society International (OARSI) re-
cently published guidelines and recommendations for clin-
ical trials in hand OA [10]. Despite initial evidence for good
efficacy of HCQ, there has not been a randomized, double-
blind, and placebo-controlled trial in a larger patient group.
In the European League Against Rheumatism (EULAR)
evidence-based recommendations for the management of
hand OA, HCQ was not included as therapeutic option be-
cause of the current lack of randomized clinical trials [11].
The evidence of HCQ in hand OA has never been inves-
tigated in controlled randomized studies, although there
are clinical indications for good effectiveness in daily rheu-
matologic practice. Until now, HCQ is only used for hand
OA in daily practice once all other available therapies have
failed. HCQ treatment of patients with other rheumatic dis-
eases shows that the drug is very well tolerated if manage-
ment for the prevention of possible side effects (e.g.
retinopathy) is carried out adequately. In vitro studies have
shown that HCQ decreases the production of TNF-α, IL-6
and IFN-α by mitogen-stimulated peripheral blood lym-
phocytes [12]. A dose-dependent inhibition of TNF-α, IL-
1β, and IL-6 by endotoxin-stimulated whole blood was also
noted [13]. Monotherapy of systemic lupus erythematosus
(SLE) patients with chloroquine results in a decrease in
serum levels of IL-6, IL-18, and TNF-α [14]. It has been
suggested that inhibition of TNF-α production by antimal-
arial drugs, which mainly affect monocytes, may be inde-
pendent of the lysomotropic action of the drugs and related
to nuclear effects [15]. HCQ acts as prostaglandin antagon-
ist by inhibition of phospholipase A2 [16]. Rheumatoid
arthritis (RA) and inflammatory OA synovial tissue have a
similar pro-inflammatory and anti-inflammatory cytokine
profile. OA cartilage shows lower production of proteogly-
cans, type II collagen, and IL-1β [17]. Moreover, HCQ po-
tentiates Fas-mediated apoptosis of synoviocytes [18]. This
background and the knowledge of the effectiveness in RA
patients raise the question of whether this drug may also be
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modulatory agents, antimalarial drugs have a favorable safety
profile. Our understanding of the toxicities and modes of
action of these drugs may suggest new applications and
modified treatment regimes in hand OA where there is huge
unmet clinical need. On the other hand, more studies are
needed to further explore the relationship between self-
reported and radiographic outcomes and the relationship
with other domains such as biomarkers and other imaging
modalities [10,19-21].
The aim of OA TREAT is to investigate the efficacy of
HCQ by clinical and radiological outcomes compared to
placebo in patients with severe and refractory inflamma-
tory hand OA. The co-primary hypotheses are that pa-
tients receiving HCQ have a lower Australian-Canadian
OA Index (AUSCAN) score in the dimensions for pain
and hand disability at week 52 and that they have a lower
rate of radiographic progression from baseline to week 52
compared to patients receiving placebo.
Methods/Design
Trial design
The trial is based on a call of investigator initiated trial
funding 2009 by the German Ministry of Education and Re-
search (Bundesministerium für Bildung und Forschung
[BMBF]) and is carried out with German rheumatologic
and statistical stakeholders with experience of treating hand
OA. OA TREAT is a multicenter, double-blind, placebo-
controlled phase III trial with a parallel group design.
Study setting
Recruitment aims are based on the design of the study as a
national multicenter study and on the established cooper-
ation with primary care physicians within the Regional
Collaborative Arthritis Centers (Department of Rheumatol-
ogy and Clinical Immunology, Charité - Universitätsmedi-
zin Berlin, German Competence Network Rheuma, HIT
HARD Trial Network). All selected centers are very experi-
enced in trial performance and approved by the local ethic
committees (EC) in their quality management as a clinical




Patients with hand OA according to the classification cri-
teria of the American College of Rheumatology (ACR) with
recent X-ray of the hands [22], dating from less than six
months and showing radiological signs of digital erosive
OA as defined by grades 2 or higher, per the Kellgren and
Lawrence scale in one or more joints [23].
Participants must meet the inclusion and exclusion cri-
teria in order to participate. These will be assessed at thescreening visit. The key inclusion and exclusion criteria
are listed in Table 1.
A total of 510 patients with erosive and inflammatory
hand OA will be recruited and randomly allocated to
either the treatment or placebo group. Recruitment
methods will include advertisements through the local
media and community groups, invitations to previous
study participants who have given their consent to be con-
tacted regarding future research projects and liaisons with
general practitioners, rheumatologists, orthopedists, and
German patients associations (for example, Rheumaliga).
Intervention
Both groups receive standard therapy (NSAID, coxibs) for
OA treatment, taken steadily two weeks before enrollment
and continued afterwards (Figure 1). If disease activity in-
creases, the dose of NSAID/coxibs can be increased ac-
cording to the drug recommendation.
Group I receives capsules with 200 to 400 mg HCQ as an
oral application from day 1 up to the end of week 52.
Group II receives capsules as an oral placebo application
from day 1 up to the end of week 52. In both groups, a
radiological examination is performed at week 52 (Figure 1).
Rescue treatment with acetaminophen (maximum of 4 ×
500 mg/d) is possible. Ongoing physiotherapy or occupa-
tional therapy before screening can be continued un-
changed, but must not be commenced after enrollment.
The time schedule of enrollment, interventions, trial
assessments, and visits for participants is described in
Table 2.
Outcomes
OA TREAT examines a number of clinical, radiographic
and patient-reported outcomes. These are listed in Table 3.
Methodological aspects
Sample size
Our sample size considerations are based on the EULAR
recommendations for the planning of RCTs in patients
with hand OA [13]. We considered differences in change
scores in the AUSCAN scales pain and hand function,
which were observed in RCTs comparing NSAIDs (lumi-
racoxib or ibuprofen) with placebo as clinically relevant
differences that also should be detected with a sufficient
power in this RCT. For these reasons, we aim to detect an
effect size (ES) of 0.4 for pain (SD: 4.3) and of 0.25 for
function (SD: 7.3) [13,29]. An ES of 0.25 is also considered
to be relevant for changes in the radiographic scores.
Based on these assumptions, a sample size of n=255 per
group is sufficient to achieve a power of 95% for the mul-
tiple endpoint test (first primary hypothesis) and an 80%
power for the second primary endpoint (radiographic pro-
gression). The sample size is also sufficient to achieve an
Table 1 Key selected inclusion and exclusion trial criteria for patients
Key inclusion criteria Key exclusion criteria
1. Men and women from 40 to 80 years of age. 1. Patients who are currently treated with hydroxychloroquine (HCQ) or
have received HCQ in the past due to OA of the hands.
2. Presence of clinical hand osteoarthritis (OA) according to American
College of Rheumatology (ACR) criteria.
2. Patients who have not tolerated HCQ (for example, skin disease or
malaria prophylaxis) or patients for whom HCQ was discontinued due
to an eye disease.
3. Conforming to the ACR criteria for hand OA supported by X-ray of
both hands, dating less than 6 months previous, X-ray of the hands
showing radiological signs of digital erosive OA in one or more joints.
This criterion is checked by a central assessment.
3. Existence of a pain syndrome of the upper limbs, which would interfere
with the monitoring of pain.
4. Symptoms of digital inflammatory OA (pressure pain of the joint and/
or florid joint swelling and/or redness and/or warmth) with more than
three fingers’ joints for more than 3 months (at least every other day)
despite taking analgesics and non-steroidal anti-inflammatory drugs
(NSAIDs).
4. Patients suffering or having suffered from secondary OA after one of
the following disease (for example, infectious arthritis, acromegaly,
ochronosis, hemochromatosis, gout, etcetera) or inflammatory joint
diseases.
5. Pain above 4 as evaluated by the Australian-Canadian OA Index
(AUSCAN)-numeric rating score (NRS) (0-10).
5. Planned surgery.
6. Function as co-primary clinical outcome with ≥26 using the AUSCAN. 6. Local injection of finger or hand joints with glucocorticoids or other
medications in the previous 3 months.
7. The ability to understand the trial information for patients
(Arzneimittelgesetz, German Medicinal Products Act (AMG) §40(1) and 3b).
7. Current intake of oral, intra-articular (i.a.) or systematic glucocorticoids
(intravenous (i.v.), intramuscular (i.m.)).
8. The ability to sign the written informed consent form including the
data protection form (according AMG §40(1) and 3b).
8. Presence of retinopathy.
9. Known hypersensitivity to HCQ or to one of the drugs in this study
protocol.
10. Treatment with digoxin
11. Any unstable medical condition or other serious clinical situations that
expose the patient to risk in the opinion of the local investigator.
12. Current participation in another clinical trial or undergoing an
experimental treatment.
13. Patients who are underage or incapable of understanding the aim,
importance and consequences of the study or of giving legal
informed consent (according to AMG §40(4) and 42(2) and (3)).
14. Prisoners and persons who are institutionalized due to AMG §40(1),
no. 4
15. Pregnant and breastfeeding women
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subscales pain and hand function separately.
Randomization, treatment assignment and allocation
concealment
Randomization will be undertaken during normal working
hours (Monday to Friday from 9:00 to 17:00) by the
German Rheumatologic Research Center (Deutsches
Rheumatologisches Forschungszentrum, DRFZ) of partici-
pating centers upon receipt of a randomization request
form and after blinded review of X-rays of both hands.
Identical HCQ and placebo capsules will be produced to
ensure allocation concealment. Upon production, study
medication will be packed into numbered bottles accord-
ing to a randomization schedule. This will be prepared by
the DRFZ using a computerized random number gener-
ator, thereby guaranteeing full allocation concealment.Trial medication will be issued in numerical order by the
pharmacy of the Charité - Universitätsmedizin Berlin. Par-
ticipants in each site will be randomly assigned to the
intervention arm or the placebo arm in a ratio of 1:1 and
the randomization will be double-blind.
Blinding
As this is a double-blind study, all parties involved includ-
ing the investigator, study coordinator, and subject will re-
main blinded to each subject’s treatment throughout the
course of the study. The blind will be maintained at all
times until all data has been collected and the study data-
base locked. Participants will be randomized centrally by
computer generated random numbers stratified by center.
Patients and investigators are blind to the treatment allo-
cation. A sealed envelope containing the blinded informa-
tion will be provided to the investigator and retained by
Figure 1 Trial overview.
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be opened in the case of emergency. Unopened envelopes
will be returned to the sponsor at the end of the study.
Use of NSAIDs and rescue medication (acetaminophen)
will be assessed carefully throughout the trial. The pos-
sible influence of these drugs on the outcome will be dis-
cussed. Radiographs will be read in a concealed time order
by two readers blinded to treatment assignment.
Statistical methods
All patients who received at least one dose of the study
medication will be included in the statistical analysis of
the efficacy and safety of HCQ (modified intention-to-
treat (mITT) population). To control the familywise
error rate of 5%, a closed test procedure was applied[30]. In the first step, the first primary hypothesis is
tested by means of the multiple endpoint tests according
to Läuter and O’Brian [31]. Using this test the outcome
in the AUSCAN scales pain and hand function at week
52 is compared between the treatment groups. The mul-
tiple endpoint test compares a standardized sum of both
outcome measures (AUSCAN pain and function). Since
we can assume that the outcome in pain and hand func-
tion are correlated, this test is more powerful than a
Bonferroni-type test procedure or Hottelling’s T2 test
[30,32]. In the case of a significant difference of the first
primary hypothesis, the second primary hypothesis
(radiographic outcome at week 52) will be tested by
means of an analysis of covariance (ANCOVA) based on
ranks (nonparametric ANCOVA). Parametric ANCOVA
Table 2 Trial timeline, interventions, assessments and visits of OA TREAT
Primary outcome
measures:
Clinical endpoint Australian-Canadian Osteoarthritis (OA) Index (AUSCAN, German version) dimensions for pain and hand disability as
co-primary clinical outcomes at week 52.
Radiographic co-primary
endpoint:
Radiographic progression from baseline to week 52.
Key secondary endpoints:
Clinical outcomes: •Assessment and comparison of the inflammatory status using the following parameters: joint pain and joint swelling,
night pain, morning stiffness, local erythema/redness, c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
levels from baseline to week 26,52.
•Comparison of the increase or decrease of the consumption in the standard medication in the previous 7 days at each
visit (non-steroidal anti-inflammatory drugs (NSAIDs), coxibs).
Patients-reported outcomes •Patients global assessment of disease activity, patient’s assessment of stiffness, and physician’s global assessment of
disease activity from baseline to week 26,52.
•Comparison of pain, functioning, disability, quality of life, patient-acceptable symptoms and health with Health
Assessment Questionnaire (HAQ), Short Form for the Changes of Quality of Life (SF-36), Short Form for the Assessment
and Quantification of Chronic Rheumatic Affections of the Hands (SF-SACRAH), Australian-Canadian Osteoarthritis Index
(AUSCAN), etcetera from baseline to week 26, 52.
Assessment of safety:
Safety and tolerability of hydroxychloroquine (HCQ) with reports on adverse events (AE) and serious adverse events (SAE) from screening to baseline
and week 12, 26, 39, 52, and follow-up of the eyes will be performed by an ophthalmologist at baseline and every 6 months (week 26 and 52).
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compare secondary outcomes (pain, function, quality of
life parameters (SF-36)). Changes in the co-use of
NSAIDs and/or analgesics will be compared between
both groups. To estimate whether any imbalance in the
use might have influenced the outcome in pain and
function the suggestions by Dougados et al. for compar-
ing different drugs and different dosages will be consid-
ered [33]. In the unlikely case that in the verum arm the
dosages are more frequently increased by 50% or more
(including an increase from 0 mg to half of the full dos-
age), this finding will be taken into account in the inter-
pretation of the results.
Data collection and data management
All subject data obtained during the study will be recorded
using pseudonyms. Every patient will be clearly identified
by a registration number and a pseudonym, which will be
assigned during the registration process. The investigator
keeps a confidential patient list, in which the patient num-
ber and pseudonym are connected to the complete patient’s
name. Access to this list is only provided to the local study
personal and the study monitor. The original source files
and medical records directly related to the study can be
accessed by study monitors, auditors or inspectors from
regulatory authorities. All data collection of pseudonomized
data will be done on standardized case report forms (CRFs),
which will be completed by site staff, verified by the princi-
pal investigator, and returned to the clinical trials unit for
double data entry. All data will be recorded electronically at
the sponsor’s site by independent data managers. The spon-
sor will maintain a list of personnel authorized to enter datainto the database. Validation of correct data entry will be
ensured by the named data managers to check for discrep-
ancies and to ensure consistency of the data. Validated data
will be entered into an electronic trial database. Any
addition, change or correction to the entered data must be
approved by the investigator and will be recorded. Records
of correction will be kept together with the case report
form. Regular backups of the electronic data will be per-
formed. When all data have been recorded and validated
after termination of the study the database will be closed.
This process will be recorded.
The sponsor maintains a list of personnel authorized
to access the data.
Monitoring and auditing
The monitor has the responsibility to familiarize the inves-
tigator(s) and the entire center staff involved in the study
with all study procedures including the administration of
the study drug. The sponsor must provide a trained moni-
tor to assist the investigator(s) in conducting the clinical
study. The monitor must visit the clinical study center on a
regular basis and at least once before the first subject has
been enrolled, once during the course of the study, and
finally at study completion. The monitor has the responsi-
bility of reviewing the ongoing study with the investigator(s)
to verify adherence to the protocol and to deal with any
problems that arise. At all times the sponsor must maintain
the confidentiality of the study documents. It is the respon-
sibility of the study monitor to verify the study documents
against the subject’s original medical records. The investiga-
tor (or his/her deputy) agrees to cooperate with the monitor
to ensure that any problems detected in the course of these





















•Clinical, laboratory and immunological investigation
•Pregnancy test
•X-ray of both hands and assessment by two blinded reviewers X
•Ophthalmological examination
•AUSCAN Index
•Patient-reported outcomes (HQA, SF-36, SF-SACRAH)
Allocation X
Interventions:
• Hydroxychloroquine X* X* X* X* X*





•Clinical, laboratory and immunological investigation X
•AUSCAN-Index




•AUSCAN X X X X X
•X-ray of both hands X
Medication history
•Laboratory and immunological investigation X X X X X
•Patient-reported outcomes
•Accompanying research
•Safety (AE, SAE) X X X X X X
X*: The therapy is administered continuously from day 1 to week 52.
AUSCAN: Australian-Canadian OA Index (German version) for pain and hand disability. The patient-centered self-administered AUSCAN Index is a valid, responsive
and feasible tri-dimensional (pain, stiffness, and function) index developed specially for hand osteoarthritis studies [24-26].
HAQ-DI: Health Assessment Disability Index. The HAQ-DI assesses the degree of difficulty experienced in eight categories of daily living activity using 20 questions.
This questionnaire has been validated for rheumatoid arthritis (RA); there is no experience in OA hand trials.
SF-SACRAH: Short Form Score for the Assessment and Quantification of Chronic Rheumatic Affections of the Hands. The SACRAH includes visual analog scales
covering the extent of hand function, stiffness and level of pain from 0 to 100 [27]. The smallest number of questions of the modified score for the assessment
and quantification of chronic rheumatic affections of the hands (M-SACRAH) providing reasonable reliability was identified by factor analysis and calculating
Cronbach’s alpha, subsequently resulting in a five-item scale, the short form-SACRAH (SF-SACRAH) [23,27].
SF-36: Short form for the Changes of Quality of Life. The SF-36 v.2 is a 36-item generic health status measure. It measures eight general concepts: physical func-
tioning, physical role, bodily pain, general health, vitality social functioning, emotional role and mental health. These concepts can also be summarizes as physical
(PCS) and mental component (MCS) scores. This questionnaire should be completed by the subject prior to any procedures being performed at the visit, if pos-
sible. To date, there is no experience in OA hand trials. Examples of health-related quality instruments include the SF-36 [28].
AE: Adverse events.
SAE: Severe adverse events.
*: Accompanying research of biomarkers in hand OA, dental and periodontal disease, health economic cost analysis.
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toring’ of the trial master file (TMF) (www.tmf-ev.de) is uti-
lized for monitoring. The trial monitoring requires a high
degree of professional expertise of the monitor. We have a
variety of very specific outcome criteria, which are new to
the involved trial sites. The focus of monitoring will be on
developing, checking and adjusting the trial procedures, and
on providing training, mentoring and support to study staff
in response to the issues identified. In addition to the on-
site monitoring, the following activities are planned: central
monitoring of fax data and data management, training of
and information on trial staff, and specific support of trial
sites (information and download website) and investigators
(investigator meetings). Independent audits will also take
place in the course of study. The monitoring will be per-
formed for 33% of source data verification, 100% of inclu-
sion and exclusion criteria and 100% of primary endpoint
criteria. Pre-study visits prior to the start of the study were
carried out for 6 months in advance. A screening visit and
six monitor visits per trial site are planned.
Safety aspects
Data Monitoring and Safety Board
The Data Monitoring and Safety Board (DMSB) will be in-
dependent of both the investigators and the sponsor. The
DSMB will review the blinded safety data, including adverse
events reports. The DSMB will be empowered to request
the unblinding of the subject’s treatment assignment or to
recommend to the study team that this subject should be
withdrawn from the study - regardless of the treatment
assignment - if an emerging safety signal is suggested. The
constitution, governing principles, and mandate of the
DSMB are explained in the DSMB charter. The main tasks
of the DSMB are to review relevant information about the
trial; to ensure adherence to protocol; to advise whether to
continue, modify or stop a trial; and to provide the funding
organizations with information and advice.
Definition of unexpected adverse reactions
An unexpected adverse reaction (UAR) is one that is not
listed in the Summary of Product Characteristics or in the
Investigator Brochure (SmPC or IB). A UAR includes any
event that may be symptomatically and pathophysiologic-
ally related to an event listed in the labelling, but differs
from the labelled event because of greater severity or
specificity.
Definition of suspected unexpected serious
adverse reactions
Suspected unexpected serious adverse reactions (SUSARs)
are serious events that are not listed in the IB or SmPC
and that the investigator identifies as related to the investi-
gational product or procedure.
A SUSAR is defined by the following criteria: Description and severity of the SAE is not listed in
the product labeling (IB or SmPC; GCP-V § 3(9))
and is
 serious:
1. Life-threatening condition or death.
2. Initial inpatient hospitalization or prolongation of
hospitalization required.
3. Significant or persistent or disability or
incapacity.
4. Congenital anomaly/birth defect (including that
occurring in a fetus).
5. AE (GCP-V § 3(7)).
Assessment of severity
For both serious and non-serious AEs, the investigator
must determine both the intensity of the event and the
relationship of the event to study drug administration.
Intensity for each adverse event will be determined by
using the Common Terminology Criteria for Adverse
Events (CTCAE, version 4.03) of the National Cancer
Institute of the USA as a guideline, wherever possible. In
those cases where the CTCAE criteria do not apply, the
intensity of an adverse event will be defined according to
the following criteria:
Grade 1 - Mild: causing no limitations of usual
activities
Grade 2 - Moderate: causing some limitations of usual
activities
Grade 3 - Severe: causing inability to carry out usual
activities.
Grade 4 - Life-threatening: potentially life-threatening
or disabling; urgent medical intervention required
In addition, for each AE, the investigator must assess
whether the criteria for an SAE are fulfilled.
Documentation of adverse events and severe adverse
events
Any severe adverse event (SAE) and any adverse event
(AE) must be documented, whether it may or may not
be considered related to the study drug or the study pro-
cedures. The documentation includes the nature of the
event, the time point of occurrence, the duration, the se-
verity and the causal relationship of the event.
When recording an AE, the investigator should use the
overall diagnosis or syndrome using standard medical ter-
minology, rather than recording individual symptoms,
signs or changes in laboratory parameters. Laboratory pa-
rameters out of normal range must be assessed by the in-
vestigator with regard to the clinical relevance, and in case
of clinical relevance, must also be reported as an AE. Any
SAE and SUSAR, whether deemed treatment-related or
not, must be reported by telephone and fax to the sponsor
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become aware of its occurrence. The sponsor will ensure
that all relevant information about SAEs and SUSARs that
are fatal or life-threatening is recorded and reported as
soon as possible to the national authorities (Federal Insti-
tute for Drugs and Medical Devices; Bundesinstitut für
Arzneimittel und Medizinprodukte; BfArM) and to the re-
sponsible EC.
All other SAEs and SUSARs will be reported to the
BfArM and to the EC as soon as possible but within a
maximum of 15 days of first knowledge by the sponsor.
The sponsor will also inform all investigators.
Annual safety reports
Once a year throughout the clinical trial, the sponsor will
provide the national authorities BfArM and the EC with a
listing of all SAEs and SUSARs that have occurred over
this period and a report of the subjects’ safety.
Safety profile of hydroxychloroquine
The treatment is generally considered as low risk, and most
side effects are not dangerous. The drug has been used suc-
cessfully for several years in rheumatology and for malaria
prophylaxis.
Patients report frequent side effects such as loss of ap-
petite, flatulence, vomiting, diarrhea, headache, nausea,
weight loss or unusual tiredness. These symptoms occur
mainly during the first weeks of treatment.
Uncommon side effects include dizziness, blurred vision,
emotional lability, corneal clouding, hearing impairment,
hearing loss, drowsiness, numbness, sleep disturbances, diz-
ziness, tinnitus, confusion, agitation, headache, paresthesia,
decreased muscle strength, weakening of the tendon re-
flexes, changes in sensory perception, ECG changes, con-
duction disorders, heart disease, and nerve-muscle diseases.
Among the rare side effects are retina problems with
visual field defects, impaired color vision, blurred vision,
vision loss, changes in skin color, mucous membrane
discoloration, bleached hair, gray hair, alopecia, pruritus,
photosensitivity, liver problems or failure, beginning of
psoriasis, the beginning of porphyria or exacerbation of
myasthenia gravis. The very rare side effects include skin
rashes, seizures, and methemoglobinemia.
Contraindications
Eye diseases with visual field defects, retinopathy, myas-
thenia gravis, bone marrow suppression, glucose-6-Ph-
dehydrogenase deficiency, known allergy to the substance,
and breastfeeding are contraindicated. Only under strict
indications should HCQ be used when there are concerns
about hepatic and renal function, porphyria, psoriasis,
seizure disorders, or with concurrent use of monoamine
oxidases (MAO) inhibitors in pregnancy. The followingmeasures of therapeutic safety monitoring are provided in
this trial:
1. Regular collection and reporting of all adverse
events.
2. Medical control of the eyes at baseline and every
6 months.
3. Immediate notification of serious adverse event
(SAE), SUSAR, suspected expected serious adverse
reaction (SESAR), etcetera after becoming aware of
the sponsor and follow-up reports within 7 days.
4. Regular meetings of the DSMB and decisions
regarding the continuation of the study based on the
AE reports.
5. Immediate treatments stop after decision of the
investigator.
6. Regular monitoring of laboratory parameters of
therapeutic safety.
Ethics and dissemination
Regulatory approval and protocol amendments
Full ethical approval was granted by the independent EC
of Berlin (13/029, Landesamt für Gesundheit und Soziales
Berlin, LAGeSo) and by the BfArM. Full approval also was
given by the Medicines and Healthcare Products Regula-
tory Agency (EudraCT 2011-001689-16).
The study will be announced to the LAGeSo Berlin.
The sponsor and all participating investigators will be
designated by their full name and position.
All protocol modifications must be prepared by a rep-
resentative of the sponsor and initially reviewed and ap-
proved by the Trial Core Team (Medical Monitor, Trial
Project Manager, Data Safety and Biostatistician) and
Monitoring Boards. All protocol modifications must be
submitted to the appropriate Independent EC of Berlin.
The sponsor informs the BfArM and BMBF about all
protocol modifications.
Approval must be awaited before any changes can be im-
plemented, except for changes necessary to eliminate an
immediate hazard to trial patients, or when the change(s)
involves only logistical or administrative aspects of the trial
(for example, change in monitor(s), change of telephone
number(s).
Insurance
All participating patients are covered for the occurrence
of study-related health damage. According to the German
Drug Law, the sponsor of the study covers patient
insurance.
Informed consent
Before the start of the study, the patients will be edu-
cated in detail - both verbally and in writing - about the
study and the associated risks. Patients will have a
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of the investigator, or a person designated by the investi-
gator (if acceptable by local regulations), to obtain writ-
ten informed consent from each patient participating in
this study after adequate explanation of the aim,
methods, anticipated benefits, and potential hazards of
the study. For patients not qualified or incapable of giv-
ing legal consent, written consent must be obtained
from the legally acceptable representative. In the case
where both the patient and his/her legally acceptable
representative are unable to read, an impartial witness
should be present during the entire informed consent
discussion. After the patient and representative have ver-
bally consented to participation in the trial, the witness’
signature on the form will attest that the information in
the consent form was accurately explained and under-
stood. The investigator or designee must also explain
that the patients are completely free to refuse to enter
the study or to withdraw from it at any time and for any
reason. The case report form (CRF) for this study con-
tains a section for documenting informed consent, and
this must be completed appropriately. If new safety in-
formation results in significant changes in the risk/bene-
fit assessment, the consent form should be reviewed and
updated if necessary. All patients (including those
already being treated) should be informed of the new in-
formation, given a copy of the revised form and give
their consent to continue in the study.
Study termination
Patients will be informed that they have the right to
withdraw from the study at any time for any reason,
without prejudice to their medical care. The investigator
also has the right to withdraw patients from the study
for any of the following reasons (but each patient with
one application of HCQ and who is followed to X-ray
investigation of the hands at week 52 is included in the
trial analyses):
1. Intercurrent diseases.
2. Ophthalmologic changes associated with HCQ.
3. Occurrence of any grade 3 to 4 WHO toxicity or an
unacceptable adverse event.




7. General or specific changes in the patient’s condition
unacceptable for further treatment in the judgment
of the investigator.
8. Protocol violations.
9. Medical and ethical discretion of principal
investigator.
10.Failure to return for follow-up.The whole trial may be stopped for the following:
1. Administrative reasons.
2. Incidence of severe adverse events or fatal adverse
events. Stopping rules are decided jointly by the data
monitoring and safety board.
Procedure to avoid simultaneous inclusion in several
studies
To avoid simultaneous inclusion in several studies, pa-
tients who had an experimental therapy or participated in
clinical study with investigational medicinal products in
the 3 months previous to the start of the treatment are ex-
cluded from this study. After a time interval of 3 months,
inclusion of these patients is possible.
Confidentiality
Before the trial started, all local trial investigators gave
written statements about conflicts of private, economical
or financial interests with regard to the above-
mentioned clinical trial and the investigational drugs
that will be used.
Declaration of interests
The investigator will ensure that this study is conducted
in full conformance with the principles of the ‘Declaration
of Helsinki’ or with the laws of the country in which the
research is conducted, whichever affords greater protec-
tion to the individual (in Germany for example, AMG/16.
Novelle 2013). The study must fully adhere to the princi-
ples outlined in ‘Guideline for Good Clinical Practice’ ICH
Tripartite Guideline (January 1997) or to local law if it af-
fords greater protection to the patient.
Strategies for dissemination of results, dissemination policy
The results of the OA Treat study will consecutively im-
prove the quality of rheumatologic treatment in Germany.
The results will be analyzed and published independently
of the pharmaceutical industry. Another important aspect
is the implementation of the results of this study into the
guidelines ‘Quality Assurance in Rheumatic Diseases’ and
the ‘German Recommendations for Physicians - GC’ (www.
dgrh.de), which have been developed by the working group
of the German Society of Rheumatology (DGRh). The re-
sults of this study will be presented at scientific meetings
and published in peer-reviewed scientific or medical jour-
nals. The study will be registered with the European
Science Foundation as part of an effort to achieve
European-wide registration of all randomized controlled
clinical trials; it is possible that the results will spark inter-
national discussions in scientific circles to allow for the pos-
sibility of extrapolating the findings to other conditions.
The cooperation with the Competence Network Rheuma-
tology, the DRFZ and the various national trial centers
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other therapy options in the treatment of OA. Also, other
medical disciplines, in which the disease is often treated,
can benefit from these results. For this reason, the dissem-
ination of the results in general medical journals and inter-
disciplinary conferences is planned.
Discussion
Inflammatory and erosive OA of the hands is a chronic
disease that severely impacts the quality of life not only in
older people but also the younger working population.
Treatment options are currently limited to symptomatic
therapy and (rarely) surgical intervention, with NSAIDs or
coxibs being the most frequently administered treatment.
Unfortunately, their symptom-relieving effect is often too
small, and adverse effects can be substantial. There is,
therefore, huge unmet clinical need for effective and safe
treatment options.
There are currently few therapeutic options to treat
hand OA. Often NSAIDs are prescribed. In long-term use,
however, these effective drugs have a very high risk of
gastrointestinal bleeding and impairment of the renal
function. Coxibs are alternatively available, but cardiovas-
cular side effects have been reported for both NSAIDs and
coxibs. Although clinical trials showed a trend for a good
efficacy of HCQ in hand OA, the development of the drug
was not pursued further. A major reason was the lack of
interest from the pharmaceutical industry. In the treat-
ment of RA and SLE, HCQ is a very effective drug and its
side effect profile has been known for many years. Pro-
vided that all safety measures are carried out, this drug is
very well tolerated and also safe in continuous treatment.
Hand OA is not a life-threatening illness, but leads to a se-
verely impaired quality of life due to pain. In addition to
the definition of termination criteria, safety-related param-
eters are regularly investigated and questioned (for ex-
ample, AE, SAE) during the study. Before the start of the
study, the patients will be educated in detail about the as-
sociated risks. Patients will receive a decision time of at
least 24 hours before giving written consent. Furthermore,
the patient may withdraw his consent at any time during
the study. The project will follow all regulations and legal
requirements for data protection, AMG/GCP, and the
Declaration of Helsinki.
The co-primary clinical endpoints in this study are the
changes in AUSCAN dimensions for pain and hand dis-
ability at week 52. The AUSCAN (Australian/Canadian
hand OA Index) is a patient-centered self-administered
questionnaire developed specifically for hand OA studies
[31]. It consists of three subscales and a total of 15 items:
pain subscale (rest, gripping, lifting, turning, and squeez-
ing), stiffness subscale (morning stiffness), and a physical
function subscale (turning taps/faucets, turning a round
doorknob or handle, doing up buttons, fastening jewelry,opening a new jar, carrying a full pot, peeling vegetables/
fruits, picking up large heavy objects, and wringing out
wash cloths) [31]. It has been validated in both OA and
RA patients. Associations with grip strength and radio-
graphic severity of hand OA have been demonstrated.
Post-validation experience in phase III clinical trials has
confirmed the responsiveness of the AUSCAN. Versions
with 5-point Likert scales, 100-mm visual analog scales
(VAS) and 11-point numerical rating scales (NRS) are
available [31]. In this study, we chose the NRS version as
it combines the simplicity of the Likert scale with the high
responsiveness of the VAS. The most commonly used ap-
proach to analyze the questionnaire is by summation of
the 15 components (total AUSCAN score), resulting in
scores between 0 and 150 [31].
The following potential limitations of the study should
be noted: generalizability of the results may be limited
by specific inclusion and exclusion criteria, and results
may not apply to the entire target population. However,
selection criteria were kept as broad as possible to en-
sure maximal generalizability. For ethical reasons,
changes in the NSAID dosages including new treatment
starts or treatment terminations are allowed. Since an
imbalance in the use of co-medications might have an
influence on the outcome in the clinical parameters, the
use of NSAID/analgesics is recorded at each study visit
and will be analyzed as a secondary outcome. In case
there is any imbalance, we anticipate an increased use of
co-medication in the placebo group, which could
weaken the differences between both treatment arms es-
pecially regarding the AUSCAN scales for pain and hand
function. However, even if this increased use of
NSAIDs/analgesics would reduce the assumed effect
sizes for both scales by 25%, the power of the multiple
endpoint test comparing the first primary outcome will
be greater than 80%. In the unlikely case of an increased
use of NSAIDs and/or analgesics in the verum arm, this
observation will be considered in the interpretation of
the findings to discuss the possibility of a false positive
result.
HCQ has been used since the 1950s for the treatment of
various rheumatic and dermatologic diseases. It is also used
for inflammatory erosive OA in clinical practice, but there
are no high-quality clinical trials to support its use in hand
OA. Three pilot studies of HCQ in EOA are available, but
their results are contradictory, population sizes are small,
and there is a lack of standardized outcome measures. Des-
pite a favorable safety profile and initial evidence for good
efficacy of HCQ, there has not been a randomized, double-
blind, and placebo-controlled trial in a larger patient group.
HCQ was therefore not included as a therapeutic option in
the EULAR evidence-based recommendations for the man-
agement of hand OA [11]. To close this gap, we are cur-
rently performing the trial OA TREAT to investigate the
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pared to placebo in patients with severe and refractory in-
flammatory hand OA. In contrast to other current studies
on symptomatic hand OA, for example, HERO [34], OA
TREAT focuses on erosive hand OA, a more severe subset
of hand OA with very limited therapy options.
Trial status
Recruitment and follow-up of participants are in progress.
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